Intuitive Surgical: The End of a Two-Decade Monopoly Has Investors Rethinking Everything
Published on 08/02/2026 at 14:32 | Redaktion boerse-global.de
For nearly 25 years, the operating room belonged to da Vinci. That era officially ended on July 22, when the FDA granted Johnson & Johnson's Ottava surgical robot De-Novo clearance for ten general surgery procedures — from Roux-en-Y gastric bypass and gastrectomy to cholecystectomy, splenectomy, sleeve gastrectomy, small bowel resection, appendectomy, adhesiolysis, fundoplication, and hiatal hernia repair.
The approval is no niche carve-out. It strikes directly at the heart of Intuitive Surgical's dominance in soft-tissue robotic surgery, a market where the company has commanded an estimated 70 percent share. And J&J isn't tiptoeing in: the healthcare giant is launching commercial sales at select US customers immediately, with plans to expand into additional indications and geographies.
The Market Has Already Delivered Its Verdict
Investors didn't wait for the rollout to play out. The stock has shed roughly 40 percent from its January high of 516.50 EUR, trading at 306.80 EUR — a level that marks a 37.28 percent decline since the start of the year. The day after the Ottava approval, shares touched a 52-week low of 289.05 EUR.
Friday brought modest relief, with the stock up 0.25 percent to 306.80 EUR and gaining 3.37 percent on the week. But the technical picture remains strained: the RSI sits at 39.3, suggesting selling pressure is easing, yet the shares trade 11.58 percent below their 50-day average and well off the 200-day level of 415.98 EUR.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
Not Just One New Rival
Ottava isn't the only challenger at the gate. Medtronic's Hugo system received FDA clearance for urological procedures in late 2025. Within twelve months, Intuitive has gone from facing speculative competition to confronting two well-capitalized entrants with regulatory approval in hand.
The shift in narrative is stark: "competition might come" has become "competition is here, with a regulatory stamp." That transition has fundamentally altered how the market prices the stock. What was once a premium valuation supported by uncertainty about potential rivals is now being repriced against a concrete, dated competitive threat.
The Operational Reality Is More Nuanced
For all the drama in the share price, the underlying business hasn't collapsed. Second-quarter revenue rose 19 percent to 2.89 billion USD, beating analyst expectations. The company's guidance for procedure growth, however, was cautious — US growth slowed to around 12 percent, the weakest pace since 2021.
Management still projects 13 to 15 percent worldwide da Vinci procedure growth for 2026, slower than last year but hardly a crash. The company attributes the deceleration to a mix of factors beyond competition: shifting US reimbursement rules, investment hesitancy in Europe and Japan, and evolving market dynamics in China.
That broader context helps explain why the drawdown feels outsized relative to any single competitive headline. J&J itself describes Ottava as a long-term project that must still win over additional indications and regions. The rollout is explicitly limited and gradual — not an overnight transformation of surgical practice.
What's Still Working in Intuitive's Favor
The installed base remains formidable. As of June 30, 11,710 systems were in operation worldwide, securing recurring revenue from instruments and accessories. The da Vinci 5 system accounted for over 50 percent of new system placements last quarter — a signal that adoption of the latest platform continues to gain traction.
Intuitive's surgeon training network, 25 years of accumulated procedural data, and entrenched hospital relationships don't evaporate because a competitor received clearance for ten procedures. These assets underpin the bull case that the market may be overcorrecting.
Intuitive Surgical at a turning point? This analysis reveals what investors need to know now.
Analysts Are Split, but the Average Says Buy
Wall Street's response has been anything but uniform. HSBC downgraded the stock to "Hold" in late July, citing near-term growth concerns. UBS initiated coverage with a "Buy" rating and a 500 USD price target, arguing the market has overstated the competitive threat — and that advancing automation will ultimately accelerate the adoption of robotic surgery across the board. Bank of America reportedly added to its position on July 31.
The consensus price target stands at 413.68 EUR, roughly 35 percent above the current price. That gap suggests the sell-side isn't writing off Intuitive's market position, even as it fully incorporates the new competitive landscape into valuations.
What to Watch Next
The first week of August brings two macro events that could move the stock. Monday, August 3, sees the release of the US ISM manufacturing PMI, offering clues on industrial investment appetite. Friday, August 7, brings the US jobs report, which will shape expectations for Federal Reserve policy and, by extension, valuations across the medtech sector.
With annualized volatility near 58 percent and the share price hovering just above its fresh yearly low, the repricing process looks far from complete. The question now is whether the 289 EUR technical level holds against the macro headwinds — and whether the market's new, more sober view of Intuitive's competitive position has fully found its floor.
Ad
Intuitive Surgical Stock: New Analysis - 2 August
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
